Context: The homogeneous distribution of BRAF V600E in papillary thyroid carcinoma (PTC)
has been called into question by recent reports. These studies claim that BRAF V600E is …

The activating mutation BRAF T1796A is the most prevalent genetic alteration in papillary
thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this …

Abstract Background The BRAF V600E mutation is the most common genetic alteration
found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more …

Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid
carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of …

Objective Genetic alterations in four oncogenes, namely RAS point mutations, RET
rearrangements (RET/PTC), NTRK1 rearrangements (TRK) and BRAF point mutations have …

Context: Evaluation of the degree of neoplastic infiltration beyond the thyroid capsule
remains a unique parameter that can be evaluated by histopathological examination to label …

Summary objective Recently, a somatic point mutation of the BRAF gene (V599E) has been
identified as the most common genetic event in papillary thyroid carcinoma (PTC) with a …

BACKGROUND: The role of the B-isoform of the Raf kinase (BRAF) mutation BRAFV600E
as an independent prognostic factor in papillary thyroid cancer (PTC) remains controversial …

Mutations in the BRAF gene have recently been detected in a wide range of neoplastic
lesions with a particularly high prevalence in melanoma and papillary thyroid carcinoma …

Abstract BRAF (V600E) mutation is the most frequent genetic alteration in papillary thyroid
carcinomas (PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship …